Acute Intermittent Porphyria Market: Recurrent Attacks, Monthly RNAi Treatment, and Reimbursement Restrictions Shape Revenue

The Global Acute Intermittent Porphyria Market was valued at USD 1.25 billion in 2025 and is projected to reach USD 3.09 billion by 2032, growing at a CAGR of 13.8%, according to Strategic Market Research.

 

The market operates through two main pharmaceutical pathways. Intravenous hemin treats acute neurovisceral attacks requiring urgent intervention, while givosiran creates recurring demand through monthly preventive administration. Liver transplantation is reserved for a small group of patients with severe refractory disease and does not form a commercially comparable treatment segment.

 

Revenue depends on how many people develop active disease, receive biochemical confirmation, experience treatment-requiring attacks, reach a porphyria specialist, qualify for reimbursement, and remain on preventive therapy. Low disease penetrance creates a wide gap between people carrying an HMBS variant and patients generating drug, hospital, infusion, and specialist-care expenditure.

 

Low Genetic Penetrance Restricts the Treatable Population

GeneReviews estimates that pathogenic HMBS variants occur in approximately 1 in 1,299 people in studied sequencing populations. General-population penetrance is only 0.5%–1%, leaving most carriers without clinically active acute intermittent porphyria. Genetic prevalence therefore provides a poor basis for estimating treatment demand.

Symptomatic disease is considerably less common. Overt AIP, defined by at least one acute attack, has been estimated at 1 in 132,000 people in France. Across Europe excluding Sweden, symptomatic prevalence was approximately 5.4 per million, while annual incidence was only 0.12 newly diagnosed cases per million.

Mortality from acute intermittent porphyria has declined substantially with early diagnosis and hemin-based treatment, and deaths from acute attacks are now considered rare. Patients with severe or recurrent attacks may still have higher long-term mortality, particularly from chronic kidney disease and hepatocellular carcinoma. Historical studies reported acute-attack fatality rates of 21%–59%, but these figures largely reflect outcomes before modern treatment became available.

Each stage of the patient pathway reduces the number entering treatment. Genetic confirmation may lead only to counselling, medication review, and trigger avoidance. A person with one historical attack may not require continuing pharmacotherapy. Preventive treatment generally requires active disease, recurrent attacks, specialist assessment, and payer authorization.

Broader genetic testing can identify more HMBS variant carriers, but manufacturers gain little revenue unless testing leads to biochemical confirmation and treatment eligibility. Diagnostic programs must separate latent genetic risk from clinically active disease instead of treating every carrier as a potential therapy user.

 

Diagnostic Delays Keep Symptomatic Patients Outside Treatment

AIP frequently enters the healthcare system through severe abdominal pain, vomiting, constipation, hyponatremia, seizures, neuropathy, hypertension, or behavioral changes. These manifestations overlap with gastrointestinal, neurological, psychiatric, gynecological, and surgical conditions, resulting in repeated consultations before porphyria testing is ordered.

An observational study covering acute porphyrias, including 90 patients with AIP, reported an average diagnostic delay of approximately 15 years. Some patients underwent appendectomy or cholecystectomy before clinicians suspected porphyria. Delayed identification reduces hemin use during early attacks and prevents eligible recurrent patients from entering preventive treatment.

Biochemical testing determines whether a suspected patient reaches specialist care. GeneReviews defines an acute attack through a urine PBG-to-creatinine ratio at least ten times the upper limit of normal, together with two or more compatible manifestations lasting longer than 24 hours when no alternative explanation is present.

Random urine measurement of porphobilinogen, delta-aminolevulinic acid, and creatinine provides the most direct route from suspected attack to treatment. Urine porphyrins alone are less useful because secondary elevations can occur in other diseases. HMBS genetic testing follows biochemical evidence to confirm AIP, distinguish it from other acute hepatic porphyrias, and support family testing.

Hospitals without rapid access to PBG and ALA testing may lose treatment time while samples are sent to reference laboratories. Diagnostic laboratories, emergency departments, neurologists, gastroenterologists, hematologists, and specialist porphyria centres influence market access because neither acute drug use nor preventive reimbursement can begin until active disease is documented.

 

Recurrent Attacks Define the Preventive-Treatment Segment

Approximately 3%–8% of people with AIP, predominantly women, experience recurrent disease with at least four attacks in one year. These patients account for the highest use of hemin, emergency departments, inpatient services, and specialist care, making them the principal population for monthly preventive treatment.

Reimbursement policies narrow the population further. NICE restricts publicly funded givosiran to clinically confirmed severe recurrent acute hepatic porphyria with at least four attacks during the preceding 12 months. Patients with less frequent attacks may fall within the regulatory indication but remain outside the reimbursed segment.

Porphyria centres, biochemical testing, attack documentation, family screening, and prior-authorization support influence treatment initiation more than broad primary-care promotion. Losing one eligible patient through delayed diagnosis or failed reimbursement carries greater revenue impact than it would in a high-volume pharmaceutical market.

 

Treatment Demand Divides Between Acute Rescue and Long-Term Prevention

Hospital-Based Hemin Treatment Sustains Acute-Attack Revenue

Intravenous hemin remains the principal pharmaceutical treatment for moderate and severe AIP attacks. It suppresses the liver pathway responsible for excess production of toxic porphyrin precursors, helping control abdominal, neurological, cardiovascular, and metabolic complications before they progress.

The Global Hemin Market was valued at approximately USD 555 million in 2026 and is projected to reach USD 901 million by 2035, expanding at a CAGR of 5.5%. The United States accounted for an estimated USD 254 million in 2026 and is expected to reach USD 412 million by 2035, growing at a CAGR of 4.0%. These figures cover the wider hemin market rather than AIP alone, but acute porphyria treatment remains one of its most commercially important specialized uses.

The United States represented approximately 45.8% of global hemin revenue in 2026, based on the stated market values. Strong hospital access, established porphyria treatment centres, specialist prescribing, and the commercial availability of PANHEMATIN support this concentration. U.S. hemin revenue is projected to increase by approximately USD 158 million between 2026 and 2035, while the global market is expected to add around USD 346 million.

The dominant global product format is the 350 mg single-dose injection vial. In the United States, PANHEMATIN is supplied as a 350 mg lyophilized powder for intravenous administration. Standardized single-dose packaging supports hospital inventory control, weight-based dosing, preparation by trained staff, and rapid use during acute attacks.

Hemin sales are linked to the number and severity of treatment-requiring attacks rather than the total number of HMBS variant carriers. A serious episode may require several consecutive days of intravenous treatment, generating product sales alongside pharmacy preparation, infusion services, laboratory monitoring, and specialist care.

Monthly preventive therapy can reduce attack frequency, but breakthrough attacks continue to require immediate hemin access. Hospitals and porphyria centres must therefore maintain product stocks and trained infusion capacity, preserving acute-treatment revenue even as givosiran expands within recurrent disease management.

Repeated prophylactic hemin can contribute to iron accumulation, thrombosis, and venous-access complications. These limitations encourage eligible patients to move toward non-intravenous preventive treatment, while hemin retains its established role in hospital-based rescue care.

 

Carbohydrate Therapy Serves Mild or Early Attacks

Oral carbohydrate intake or intravenous glucose may be used during mild attacks or while hemin is being arranged. Hospitals cannot rely on carbohydrate therapy once severe pain, neurological involvement, progressive weakness, or respiratory complications develop.

A recruiting clinical study is evaluating the effect of a carbohydrate-rich diet on insulin, glucose, amino acids, inflammatory markers, gut microbiota, and PBG in AIP. The study concerns nutritional management rather than a new branded medicine, limiting its direct commercial importance.

 

Liver Transplantation Remains a Rescue Option

Liver transplantation can correct hepatic HMBS deficiency and prevent further attacks, but donor limitations and surgical risk restrict use to severe pharmacotherapy-refractory disease. A European study covering 38 transplanted AIP patients reported survival of 92% at one year and 82% at five years. Half of the cohort had a glomerular filtration rate below 60 mL/min before transplantation, reflecting advanced disease among selected recipients.

Transplantation removes a small number of patients from recurring pharmaceutical treatment rather than creating a meaningful procedure-led market.

 

GIVLAARI Revenue Confirms a High-Value Rare-Disease Category

Alnylam reported GIVLAARI revenue of USD 308.5 million in 2025, up by USD 52.6 million from USD 255.9 million in 2024. The increase represents annual revenue growth of approximately 20.6%, reported by the company as 21%.

U.S. revenue reached USD 205.7 million and accounted for approximately 66.7% of global GIVLAARI revenue in 2025. Europe generated USD 77.7 million, equal to around 25.2%, while other international markets contributed USD 25.1 million, or approximately 8.1%.

GIVLAARI revenue covers all acute hepatic porphyria subtypes and cannot be classified entirely as AIP sales. AIP represented 89 of the 94 ENVISION participants, but trial composition does not establish the subtype distribution of commercial prescriptions or revenue.

Established orphan-drug reimbursement, specialist treatment centres, and greater acceptance of premium specialty medicines support the U.S. revenue lead. European revenue remains divided across country-specific pricing reviews, reimbursement agreements, and eligibility rules.

 

HMBS mRNA Remains a Preclinical Replacement Strategy

Lipid-nanoparticle HMBS messenger RNA generated dose-dependent hepatic protein expression and rapid reductions in ALA and PBG in animal models. The approach could restore deficient enzyme activity without permanently modifying DNA.

Repeated dosing, duration of effect, immune tolerability, liver targeting, and manufacturing consistency remain unresolved. Public evidence has not established a late-stage candidate or expected approval date.

 

Pharmacological Chaperones Could Support Oral Treatment

Experimental chaperones are designed to stabilize mutant HMBS proteins and increase residual enzyme activity. Preclinical compounds have improved HMBS stability and biochemical function in cellular and animal models.

An oral medicine would offer a convenience advantage over intravenous hemin and healthcare-professional-administered givosiran. Mutation-specific activity could divide an already small patient population and complicate clinical recruitment.

 

Enzyme Replacement Still Faces Delivery Limitations

Recombinant HMBS enzyme replacement entered early research but encountered short circulation time and weak liver targeting. A viable product would require sustained hepatocyte delivery and sufficient enzyme activity without frequent infusions.

Givosiran and hemin will retain their established positions while replacement technologies remain preclinical or early stage. New entrants must demonstrate durable attack prevention, manageable hepatic and renal safety, simpler administration, and payer value against an approved preventive therapy with long-term follow-up.

 

Diagnosis, Reimbursement, and Retention Will Determine Market Expansion

AIP incidence is too low to generate rapid volume growth independently. Market expansion depends on shortening diagnostic delays, confirming active disease, documenting recurrent attacks, obtaining payer authorization, and keeping patients on treatment.

GIVLAARI’s approximately 20.6% annual revenue increase in 2025 exceeded the projected 13.8% CAGR of the wider Acute Intermittent Porphyria Market. The comparison indicates strong recent growth in the established preventive product, although GIVLAARI revenue includes all acute hepatic porphyria subtypes and its one-year product growth should not be treated as a long-term AIP subsegment CAGR.

Australia’s 2026 PBS listing created another publicly funded treatment channel without any change in underlying prevalence. Hemin will retain demand because breakthrough attacks continue, preventive access remains restricted, and not every eligible patient begins or persists with givosiran. Monthly RNAi treatment will capture the highest recurring pharmaceutical revenue among patients meeting attack-frequency and reimbursement requirements.

Porphyria centres, diagnostic laboratories, reimbursement teams, and patient-support services will determine how much of the limited clinical population becomes sustained commercial demand. Product revenue, diagnostic conversion, attack utilization, treatment eligibility, payer decisions, and treatment persistence provide stronger measures of market performance than genetic prevalence alone.

 

Acute Intermittent Porphyria Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.25 Billion
Revenue Forecast in 2032	USD 3.09 Billion
Overall Growth Rate	CAGR of 13.8% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product, By Application, By End User, By Geography
By Product	Hemin Products (Hematin, Heme Arginate); RNA Interference Therapeutics (Givosiran); Carbohydrate-Based Therapies (Intravenous Glucose, Oral Carbohydrate Therapy); Supportive and Adjunctive Medicines (Analgesics, Antiemetics, Antihypertensive Medicines, Anticonvulsants); Diagnostic Products (Urinary PBG and ALA Tests, HMBS Genetic Tests)
By Application	Acute-Attack Treatment, Recurrent-Attack Prevention, Biochemical and Genetic Diagnosis, Long-Term Renal and Liver Monitoring
By End User	Hospitals and Emergency Departments, Porphyria and Rare-Disease Treatment Centres, Specialty Infusion Centres, Diagnostic Laboratories, Hospital and Specialty Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, Sweden, China, Japan, India, Australia, South Korea, Brazil, Mexico, GCC Countries, South Africa
Market Drivers	- Increasing diagnosis of rare genetic metabolic disorders and improved awareness of acute intermittent porphyria. - Growing adoption of targeted therapies such as RNA interference-based treatments for recurrent attack prevention. - Rising demand for specialized diagnostic testing and multidisciplinary rare-disease care networks.
Customization Option	Available upon request